INVENTIVA Announces a U.S. Phase II Investigator-Initiated Study with Lanifibranor on Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes

    NEXT STORY
    Lux Research Releases In-Depth Benchmark Study on Sugar Replacement Technologies
    PREV STORY
    Galectin Therapeutics to Present Late-Breaker Oral Presentation at The International Liver Congress 2018
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    EyePoint Pharmaceuticals Receives FDA Approval of YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg

    - The first long-lasting, FDA approved micro-insert for up to three years of continuous ...

    author_avatar
    NASDAQ Market News

    Novavax Reports Second Quarter 2018 Financial Results

    Novavax Delivers on Key Milestones Supporting its 2018 Objectives Company to Host Conference Call ...

    author_avatar
    NASDAQ Market News

    EyePoint Pharmaceuticals Strengthens Global IP with Notices of Allowance for Two U.S. Patents Related to DEXYCU™

    author_avatar
    NASDAQ Market News